This finding is relevant to the lack of observed benefit to cognitive function in our study and subsequent phase III trials of amyloid-β immunotherapy in established Alzheimer’s disease, as cognitive dysfunction is known to correlate more closely with accumulation of tau than that of amyloid-β (Minett et al., 2016). This evidence concerns the gene MAPT and Alzheimer disease.